Abnormal metabolic phenotype in middle-aged GH-deficient adults despite long-term recombinant human GH replacement

K M J A Claessen1,*, N M Appelman-Dijkstra1,*, A M Pereira1, S D Joustra1, R de Mutsert2, K B Gast2,3, M den Heijer2, J W A Smit1, O M Dekkers1,2 and N R Biermasz1

1Department of Endocrinology and Metabolic Diseases C7-Q and Center for Endocrine Tumors, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands and Departments of 2Clinical Epidemiology and 3Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands *(K M J A Claessen and N M Appelman-Dijkstra contributed equally to this work)

Abstract

Background: Adult GH deficiency (GHD) is associated with increased cardiovascular mortality. Recombinant human GH (rhGH) replacement has beneficial short-term metabolic effects. Although these positive effects sustain during longer follow-up, the prevalence of the metabolic syndrome (MS) remains increased in comparison with population data not adjusted for the higher mean BMI in GHD adults.

Objective: To explore whether middle-aged patients with proposed physiological rhGH replacement have been normalized with respect to MS and its individual components in comparison with the general population, adjusted for age, sex, and BMI.

Methods: One hundred and sixty-one GHD patients (aged 40–70 years) were studied before the start and after 5 years of rhGH replacement, and were compared with 1671 subjects (aged 45–66 years) from the general population (NEO Study).

Results: MS proportion in GHD patients was 41.0% before the start of rhGH suppletion, increasing to 53.4% after 5 years (P<0.007). Despite chronic rhGH replacement, GHD patients had a 1.3-times higher MS proportion than the general population, independently of age, sex, and BMI (95% CI 1.1–1.5, P<0.008). The GHD population showed a different metabolic profile than the general population with similar BMI: an increased risk of hypertriglyceridemia (adjusted prevalence ratio (PR) 2.0, 95% CI 1.7–2.3) and low HDL-C (adjusted PR 1.8, 95% CI 1.5–2.2), but less hyperglycemia (adjusted PR 0.5, 95% CI 0.4–0.7).

Conclusions: Despite 5 years of rhGH replacement, GHD patients still have a different metabolic profile and more frequently MS than the general population. These differences were independent of BMI, and resemble the unfavorable metabolic profile of untreated GHD patients, pointing to question the long-term benefits of rhGH replacement.

Introduction

Growth hormone deficiency (GHD) in adults is associated with an adverse metabolic profile, including abdominal obesity, dyslipidemia, and an increased mortality risk (1, 2). Short-term follow-up studies have shown that recombinant human GH (rhGH) replacement reduced some but not all of these cardiovascular risk factors (3). Consistent effects were reported on body composition and lipid metabolism, characterized by reduction in body fat and an increase in lean body mass, and a reduction in total cholesterol (TC) and LDL-C levels (3). Based on these positive short-term metabolic effects, as well as an improvement in quality of life (QoL), rhGH replacement...
has become widely accepted as a chronic therapy in adult GHD.

Despite improvement of individual components of the metabolic syndrome (MS), the overall prevalence of the MS was not normalized in GHD patients after several years of physiological rhGH replacement (4, 5). At present, data on long-term efficacy and safety of rhGH replacement are limited and uncontrolled for the effect of aging (5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18). Recently, we have reported a further increase in BMI and MS prevalence despite 10 years of rhGH replacement (19). Thus, it can be questioned whether in the long-term rhGH replacement is able to improve or even normalize the adverse metabolic profile present in hypopituitary patients. As an ideal unselected GHD control group without rhGH replacement is not available, we selected the Leiderdorp cohort of the Netherlands Epidemiology of Obesity (NEO) Study as representation of the general population for comparison. The NEO Study is a population-based cohort study of middle-aged Dutch adults from the same geographical area as the GHD patients.

The primary aim of this study was to compare the metabolic profile, as reflected by proportion of the MS and its individual components, between GHD patients after chronic rhGH replacement and the general population, adjusted for age and sex, to assess the ability of current rhGH replacement strategies to normalize MS features. Second, we critically compared metabolic parameters between treated GHD patients and the general population, while additionally adjusting for BMI. Finally, we compared the MS proportion in GHD patients before start and after chronic rhGH replacement.

Subjects and methods

Study design

In this study, we compared the proportion of the MS and its individual components between middle-aged GHD patients and the general population. First, adult GHD patients were studied before the start of rhGH suppletion and after 5 years of rhGH replacement, to study the metabolic effects of chronic rhGH suppletion. Second, we compared chronically treated GHD patients (defined as 5 years) with the general population, using data from the Leiderdorp cohort of the NEO Study (vide infra) (20), adjusting for age and sex and subsequently with additional adjustments for BMI, to assess the ability of current rhGH replacement strategies to completely normalize MS features.

Patient selection

This study includes all consecutive patients diagnosed with adult-onset (AO) and childhood-onset (CO) GHD at the Endocrinology Department of the LUMC from 1994 onwards. Data have been prospectively collected in a database. We investigated the effects of chronic stable rhGH replacement in middle-aged GHD patients. Chronic stable replacement was arbitrarily defined as replacement for ⩾5 years, because in such a period metabolic changes induced by rhGH therapy start will have been stabilized (3, 21). We selected all GHD patients aged 40–70 years, who started rhGH replacement ≤ 2007, to enable a 5-year follow-up period. The age criterion used was chosen to match the GHD patients with middle-aged persons from the general population from the Leiderdorp cohort (vide infra) and to avoid nonpositivity. This resulted in a total inclusion of 161 eligible GHD patients (AO 155/6 CO). The six patients with CO-GHD received rhGH replacement during childhood, and restarted with rhGH replacement as this therapy became widely accepted for adult GHD patients.

Treatment protocol

GHD had been defined before start of rhGH replacement by a GH peak response to the insulin tolerance test (ITT) < 3 µg/l (glucose nadir < 2.2 mmol/l) according to current guidelines or growth hormone releasing hormone/arginine-test (GHRH/Arg) with BMI-adjusted GH cut-offs, in case of contraindications for ITT (5, 22). All patients receiving rhGH replacement during childhood were retested at the time of transition to the adult outpatient clinic, after treatment cessation for > 3 months. All patients were treated with rhGH (Genotropin Pharmacia/Pfizer, Skokie, IL, USA; Zomacton Ferring, Troy Hills, NJ, USA; or Norditropin NovoNordisk, Princeton, NJ, USA), injected subcutaneously in the evening. In all patients, GH starting dose was 0.2 mg/day, which was individually adjusted each month in the first half year to achieve serum IGF1 concentrations within the age-dependent laboratory reference range, aimed at SDS between 0 and + 2. After reaching stable plasma concentrations, this individualized dose was continued and adjusted according to the IGF1 SDS.

Adrenocorticotropic hormone (ACTH) deficiency was defined as an insufficient increase in cortisol levels (absolute value 0.55 mmol/l) after an ITT or corticotropin-releasing hormone stimulation test in case of contraindications for ITT. When secondary amenorrhea was present for >1 year, premenopausal women were
classified as gonadotropin deficient. In men, gonadotropin deficiency was defined as a testosterone level <8.0 nmol/l. Thyroid-stimulating hormone (TSH) deficiency was defined as total thyroxine (T₄) or free T₄ level <10 pmol/l in addition to ≥2 deficient pituitary axes. Hypopituitarism was adequately supplemented by hydrocortisone, L-T₄, testosterone in men, and/or estrogen in combination with progestagens (in premenopausal women only). Dosages of the hormonal replacement therapy were monitored and adjusted as required.

Patients were treated with lipid-lowering medication and antihypertensive medication according to the discretion of their attending physicians. Efficacy and safety parameters were assessed yearly, next to a routine assessment of pituitary function.

General population

The NEO Study is currently performed at the Leiden University Medical Center (LUMC) to investigate the pathways that lead to obesity-related diseases. The NEO Study is a population-based prospective cohort study of individuals aged 45–65 years, with an oversampling of individuals with overweight or obesity (BMI ≥27 kg/m²) (20). Within the NEO Study, as reference group, all inhabitants aged between 45 and 65 years from one municipality (Leiderdorp) were invited, irrespective of their BMI. Baseline measurements have been performed between 2008 and 2012. The study was approved by the Medical Ethics Committee of the LUMC and all participants gave informed consent.

We used the Leiderdorp cohort (n=1671) for comparison with our chronically rGH-treated GHD patients. GHD patients and subjects from the general population were from the same geographical area.

Study parameters

The following efficacy parameters were studied:

i) Biochemical parameters: fasting glucose, TC, HDL-C, and triglyceride (TG) levels. LDL-C concentrations were calculated by the Friedewald formula. Blood samples were taken after an overnight fast;

ii) Anthropometric parameters: body weight and height, waist circumference, hip circumference, systolic and diastolic blood pressures were measured. BMI (in kg/m²) and waist:hip ratio were calculated;

iii) Additional information on medication use and comorbidity was gathered from patient records.

Metabolic syndrome

The MS was defined according to the updated third report of the 2006 National Cholesterol Education Program’s Adult Treatment Panel (NCEP-ATP III) criteria, which required the presence of ≥3 of the following conditions (23, 24):

i) Fasting plasma glucose concentration ≥100 mg/dl or on anti-diabetic drug treatment;

ii) TG concentration ≥150 mg/dl or on lipid-lowering drug treatment (statins and/or fibrates);

iii) HDL-C concentration <40 mg/dl in men and <50 mg/dl in women, or on lipid-lowering drug treatment (statins and/or fibrates);

iv) BP ≥130/85 mmHg or on anti-hypertensive treatment;

v) Waist circumference ≥102 cm in men and ≥88 cm in women.

Assays

From 1986 to 2005, serum IGF1 concentrations were determined by RIA (Incstar, Stillwater, MN, USA) with a detection limit of 1.5 nmol/l and an interassay CV <11%. IGF1 is expressed as SDS for age- and gender-related normal levels determined in the same laboratory (21). Since 2005, serum IGF1 concentrations (nmol/l) were measured using an immunometric technique on an Immulite 2500 system (Siemens Healthcare Diagnostics, Deerfield, IL, USA). The intra-assay variations at mean plasma levels of 8 and 75 nmol/l were 5.0 and 7.5% respectively. IGF1 levels were expressed as SDS, using lambda-mu-sigma smoothed reference curves based on 906 controls (25, 26).

In GHD patients, a Hitachi 747 autoanalyzer (Roche) was used to quantify serum concentrations of glucose, TC, and TG. HDL-C was measured with a homogenous enzymatic assay (Hitachi 911, Roche). In 2003, a Roche Modular Analytics P800 replaced the Hitachi 747 with no change in the chemistry components. In the general population, glucose, TC, HDL-C, and TG levels were measured by Roche Modular Analytics P800. Samples in patients and controls were analyzed in the same laboratory. Samples of patients were obtained between 1994 and 2013; samples of controls between 2008 and 2012.

Statistical analysis

SPSS for Windows, Version 20.0 (SPSS, Inc.) was used for statistical analysis. Results are presented as mean ±S.D., unless stated otherwise. For comparison of the MS proportion in GHD patients before start and after 5 years
of rhGH suppletion, we performed the Friedman test for related fractions. Although 19 patients did not complete 5 years of rhGH replacement for various reasons (vide infra), these patients were included using the last observation carried forward method (intention-to-treat approach), thereby including the last available measurements during rhGH replacement in the analyses. Independent t-tests were used to compare crude metabolic data between 5-year rhGH-treated GHD patients and the general population. The relationships in MS (components) proportion between GHD patients after 5 years of rhGH replacement and the general population are reported as prevalence ratios (PRs), using the log-binorminal regression model using STATA Statistical Software version 12.1 (Statacorp, College Station, TX, USA), allowing direct estimation of PRs (27, 28), which is, because of the high incidence of the MS, more appropriate than logistic models that only allow estimation of odds ratios. Analyses were adjusted for age and sex, and subsequently with additional adjustments for BMI. P<0.05 is considered statistically significant.

Results
Characteristics of patients and controls
We studied 161 adult GHD patients, aged 40–70 years at the time of GHD diagnosis (Table 1). Pituitary deficiency was mainly caused by pituitary tumors or their treatment. Patients had been treated with surgery (transsphenoidal n=109/transcranial n=24) and radiotherapy (n=76). Etiological diagnoses of GHD were nonfunctioning adenoma (n=67), functioning adenoma (n=52), craniopharynima (n=12), cerebral malignancy (n=2), congenital (n=6), and other causes (n=22). Most patients had multiple pituitary hormone deficiencies (ACTH deficiency n=142, TSH deficiency n=132, FSH/LH deficiency n=120, ADH deficiency n=27), whereas only six patients had isolated GHD. Sex steroids were supplemented in 21% of female patients (n=15) and 87% of male patients (n=77).

One hundred and forty-two patients completed 5 years of rhGH replacement (Fig. 1). Reasons for preliminary discontinuation in 19 patients (11.8%) were death (n=5), malignancy (n=2), growth of primary tumor (n=2), increase in prostate-specific antigen (PSA) level (n=1), lack of subjective benefit (n=4), side-effects, carpal tunnel syndrome (n=2), weight increase (n=1), and follow-up in other centers (n=2).

At 5 years of rhGH replacement, GHD patients were compared with 1671 subjects from the general population (Table 1). Proportion of men and mean BMI were higher in patients than in the general population (P=0.006 and P<0.001 respectively).

GH dose, IGF1 SDS, and hydrocortisone dose during rhGH replacement
Mean GH doses after dose titration (1 year) and 5 years of rhGH replacement were, respectively, 0.35±0.16 and 0.37±0.19 mg/day (P=0.399). After 5 years of rhGH replacement, females received higher mean GH doses than males (0.40±0.23 and 0.34±0.17 mg/day, respectively, P=0.05).

During the entire period of rhGH suppletion, median of IGF1 SDS was within the normal range. Median IGF1 SDS increased significantly from the untreated state from −1.30 (interquartile range (IQR) −2.43, +0.16) to 0.47 (IQR −0.50, +1.93) after 5 years of rhGH suppletion (P<0.001). In males, median IGF1 SDS increased from −1.17 (IQR −2.17, +0.92) before treatment to 0.42 (IQR −0.43, +2.03) after 5 years (P<0.001); in females, median IGF1 SDS increased from −1.63 (IQR −3.04, +0.47) before treatment to 0.51 (IQR −0.57, +1.71) after 5 years (P<0.001).

Table 1: Characteristics of 161 middle-aged GHD patients before the start and after 5 years of rhGH replacement and 1671 controls representing the general population. Data are presented as mean±s.d., unless specified otherwise.

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>GHD patients, before start of rhGH (n=161)</th>
<th>GHD patients, after 5 years of rhGH (n=161)</th>
<th>General population* (n=1671)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, female (n (%))</td>
<td>72 (44.7%)</td>
<td>72 (44.7%)</td>
<td>937 (56.1%)*</td>
</tr>
<tr>
<td>Age (years)</td>
<td>54.7±8.5 (40–70)</td>
<td>59.7±8.5 (45–75)</td>
<td>56.0±6.0 (45–66)*</td>
</tr>
<tr>
<td>BMI (kg/m²) (range)</td>
<td>27.5±4.5 (19.6–57.1)</td>
<td>28.0±4.5 (18.5–53.8)</td>
<td>26.3±4.5 (17.2–57.1)*</td>
</tr>
<tr>
<td>Lipid-lowering drugs (n (%))</td>
<td>36 (22.3%)</td>
<td>78 (48.4%)</td>
<td>182 (10.9%)*</td>
</tr>
<tr>
<td>Antihypertensive medication (n (%))</td>
<td>36 (22.3%)</td>
<td>77 (47.8%)</td>
<td>402 (24.1%)*</td>
</tr>
<tr>
<td>Anti-diabetic medication (n (%))</td>
<td>8 (5.0%)</td>
<td>14 (8.7%)</td>
<td>52 (3.1%)*</td>
</tr>
</tbody>
</table>

*P<0.05 (patients after 5 years of rhGH replacement vs general population). n, number of patients; GHD, growth hormone deficiency; rhGH, recombinant human growth hormone replacement.

The Leiderdorp cohort of the NEO Study was used as control group representing the general population (20).
Mean hydrocortisone doses were 17.43 ± 12.40 and 18.18 ± 10.81 mg/day at the start and after 5 years of rhGH suppletion, respectively, indicating no significant change during follow-up. Mean fT4 levels did not significantly change during 5 years of rhGH replacement (16.2 ± 3.7 pmol/l at the start and 16.8 ± 3.7 pmol/l after 5 years of rhGH).

**MS proportion in untreated GHD patients**

Before the initiation of rhGH replacement, 66 out of 161 patients fulfilled the NCEP-ATP III criteria, resulting in an MS proportion of 41.0% in untreated GHD (37.1% in males and 45.8% in females). Hyperglycemia, hypertriglyceridemia, low HDL-C levels, hypertension, and abdominal obesity were present in, respectively, 13.0, 59.0, 47.8, 68.3, and 35.4% of the patients.

**Effects of 5 years of rhGH replacement on the MS proportion in GHD adults**

The MS proportion increased significantly from 41.0% before to 53.4% after 5 years of rhGH replacement ($P=0.007$), especially due to an increased proportion of hyperglycemia ($P=0.02$). In males, HDL-C levels decreased significantly ($P<0.001$). As indicated in Fig. 2, the increase in MS proportion was most prominent in males (from 37.1% at the start of rhGH replacement to 53.9% after 5 years, $P=0.005$). Exclusion of CO-GHD patients ($n=6$) did not significantly change these results. BMI did not significantly change over time, from 27.5 ± 4.5 kg/m$^2$ before rhGH replacement to 28.0 ± 4.5 kg/m$^2$ after 5 years ($P=0.772$).

**Comparison of MS proportion between GHD patients on chronic rhGH replacement and the general population, adjusted for age and sex**

In the general population, we observed an MS proportion of 30.3%. The MS proportion in chronically treated GHD patients was increased when compared with controls, taking into account age and sex (53.4 vs 30.3%) (adjusted PR (95% CI) = 1.4 (1.1–1.6), $P=0.001$) (Table 2). For clinical interpretation, mean laboratory values were also presented (Table 3).

**Figure 1**
Flow chart of selection and follow-up of our middle-aged GHD cohort.

Mean hydrocortisone doses were 17.43 ± 12.40 and 18.18 ± 10.81 mg/day at the start and after 5 years of rhGH suppletion, respectively, indicating no significant change during follow-up. Mean fT4 levels did not significantly change during 5 years of rhGH replacement (16.2 ± 3.7 pmol/l at the start and 16.8 ± 3.7 pmol/l after 5 years of rhGH).

**Figure 2**
Proportion of MS (components) in adult GHD patients, before the initiation of rhGH replacement and after 5 years, in comparison with the general population, separated for females (A) and males (B). We studied the MS proportion and its individual components in i) 5-year treated GHD patients in comparison with situation before the start of rhGH replacement, using the Friedman test for related fractions, and ii) between GHD patients after 5 years of rhGH replacement compared with the general population, using a log-binominal regression model with adjustments for age and BMI. Analyses were stratified for sex. MS was defined according to the NCEP-ATP III criteria (23, 24). *$P<0.05$. TG, triglycerides; BP, blood pressure; Waist, waist circumference; MS, metabolic syndrome; rhGH, recombinant human growth hormone.
Comparison of MS proportion between GHD patients after 5 years of rhGH replacement and the general population, additionally adjusted for BMI

After additional correction for BMI, besides age and sex, GHD patients still had a 1.3-times increased MS proportion when compared with the general population, despite 5 years of rhGH replacement (adjusted PR (95% CI) = 1.3 (1.1–1.5), P = 0.008) (Table 2). Both in male and female GHD patients, significantly increased MS proportion was seen when compared with the general population (Fig. 2). When looking at the individual MS components, treated GHD patients differed from BMI-matched controls with respect to glucose, TGs, and HDL-C levels (Table 2).

Discussion

This study demonstrates a high MS proportion of 41.0% in middle-aged GHD patients before the start of treatment, which further increases to 53.4% after 5 years of rhGH replacement. Especially, a higher proportion of hyperglycemia contributed to this increase, whereas the lipid profile was not affected. Despite chronic rhGH replacement, GHD patients still have a 1.3-times increased MS proportion when compared with the general population, independent of age, sex, and BMI. GHD patients still have a different metabolic profile, characterized by hypertriglyceridemia and low HDL-C, whereas the proportion of hyperglycemia is lower than that observed in the general population.

In middle-aged GHD patients, the increased cardiovascular risk profile is a main justification of rhGH replacement. Important components of this risk are dyslipidemia, manifesting as raised levels of LDL-C and TGs and reduced HDL-C levels (29). In addition, increased fat mass, reduced insulin sensitivity, and increases in inflammatory markers are often present (29, 30). Mortality is substantially higher in GHD adults than in the general population, particularly among women (1, 2).

Table 2  Comparison of MS proportion, according to the NCEP-ATP III criteria, between middle-aged GHD patients on chronic rhGH replacement and the general population. Values are expressed as number (%). Chronic rhGH replacement was defined as 5 years. MS was defined according to the NCEP-ATP III criteria (23, 24). Log-binominal regression models were applied with robust standard errors, allowing direct estimations of PRs adjusted for age and sex, and, subsequently, with additional adjustments for BMI.

<table>
<thead>
<tr>
<th></th>
<th>GHD patients (n = 161)</th>
<th>General population (n = 1671)</th>
<th>PR (95% CI)*</th>
<th>PR (95% CI)b</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting glucose</td>
<td>37/161 (23.0%)</td>
<td>539/1663 (32.4%)</td>
<td>0.5 (0.4–0.7)*</td>
<td>0.5 (0.4–0.7)*</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>106/161 (65.8%)</td>
<td>427/1666 (25.6%)</td>
<td>2.0 (1.7–2.4)*</td>
<td>2.0 (1.7–2.3)*</td>
</tr>
<tr>
<td>HDL-C</td>
<td>92/161 (57.1%)</td>
<td>418/1666 (25.1%)</td>
<td>2.0 (1.7–2.3)*</td>
<td>1.8 (1.5–2.2)*</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>109/161 (67.7%)</td>
<td>1054/1668 (63.2%)</td>
<td>0.9 (0.8–1.0)</td>
<td>0.9 (0.8–1.1)</td>
</tr>
<tr>
<td>Waist</td>
<td>69/161 (42.9%)</td>
<td>597/1669 (35.8%)</td>
<td>1.1 (0.9–1.4)</td>
<td>1.0 (0.8–1.3)</td>
</tr>
<tr>
<td>Metabolic syndrome</td>
<td>86/161 (53.4%)</td>
<td>503/1660 (30.3%)</td>
<td>1.4 (1.1–1.6)*</td>
<td>1.3 (1.1–1.5)*</td>
</tr>
</tbody>
</table>

n, number of patients; rhGH, recombinant human growth hormone replacement; GHD, growth hormone deficiency; Waist, waist circumference; PR, prevalence ratio. *P < 0.01.

bPR, adjusted for age, sex and BMI.

Table 3  Mean values of the metabolic parameters of the MS as included in the NCEP-ATP III criteria, in adult GHD patients before the start and after 5 years of rhGH replacement and the general population. Values are expressed as mean ± s.d.

<table>
<thead>
<tr>
<th></th>
<th>GHD patients, before start of rhGH (n = 161)</th>
<th>GHD patients, after 5 years of rhGH (n = 161)</th>
<th>General population (n = 1671)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting glucose (mmol/l)</td>
<td>4.8 ± 0.8*</td>
<td>5.2 ± 1.6*</td>
<td>5.5 ± 1.1</td>
</tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>2.0 ± 1.2</td>
<td>1.9 ± 0.9*</td>
<td>1.2 ± 0.8</td>
</tr>
<tr>
<td>HDL-C (mmol/l)</td>
<td>1.4 ± 0.4*</td>
<td>1.5 ± 0.5*</td>
<td>1.6 ± 0.5</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>134.0 ± 17.8</td>
<td>135.7 ± 17.1*</td>
<td>130.4 ± 16.9</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>83.9 ± 9.3</td>
<td>83.4 ± 9.5</td>
<td>83.4 ± 10.1</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>97.2 ± 11.8</td>
<td>98.6 ± 11.2*</td>
<td>91.2 ± 12.8</td>
</tr>
</tbody>
</table>

n, number of patients; rhGH, recombinant human growth hormone replacement; GHD, growth hormone deficiency; MS, metabolic syndrome. *P < 0.01; †P < 0.05 (GHD after 5 years rhGH replacement vs the general population); ‡P < 0.001 (GHD after 5 years of rhGH replacement vs GHD before the start of rhGH suppletion).
replacement has beneficial metabolic effects in the short-term, including improvement in the lipid profile, body composition, and cardiac function (3), which were reported to be sustained during long-term follow-up (14, 18), although glucose and insulin levels increase. However, despite improvement of several cardiovascular risk factors, MS prevalence remains increased (4, 5, 19). Obvious limitations of the few available long-term studies are the lack of an untreated GHD control population and difficulties with physiological rhGH replacement.

This study is the first to investigate the metabolic profile of chronically treated GHD patients in a controlled manner, taking into account not only age and sex but also BMI. In this respect, the Leiderdorp cohort represents the general population with comparable BMI distribution to that observed in other Dutch population-based studies (http://www.rivm.nl/nldemaat.rivm.2012). We demonstrated that, independent of BMI, chronically treated GHD patients have a persistently different metabolic profile than the general population, with a lower prevalence of insulin resistance, but an adverse lipid profile. It is remarkable that although this GHD cohort is thought to be adequately substituted, as reflected by mean IGF1 SDS within the physiological range as well as no hydrocortisone oversubstitution, the metabolic profile after chronic rhGH replacement resembles the profile of an untreated GHD patient, with predominantly lipid abnormalities. Additional analyses in which we compared the GHD patients before starting rhGH replacement with the general population show similar results, suggesting that the metabolic profile is not significantly influenced by long-term rhGH replacement (data not shown).

These findings give rise to several questions. First, there is an increasing awareness of intrinsic imperfections of endocrine replacement therapy in general (31), that may also well apply to GHD patients. It is questioned whether circulating total IGF1 levels truly reflect peripheral IGF1 activity, as several earlier reports indicate that measuring free unbound IGF1 levels and IGF1 bioactivity better reflect the GH/IGF1 status (32). Further study is needed to identify sensitive biomarkers to monitor rhGH replacement therapy. Second, it is previously shown that there is an optimum for GH dosing with respect to insulin resistance (33). In this respect, further lowering of the GH dose is probably needed to minimize insulin resistance. On the other hand, the MS proportion in GHD patients remained increased despite chronic rhGH replacement and resembles the metabolic profile of untreated GHD, suggesting that GHD may have irreversible effects on the cardiovascular system. In the context of increasing evidence for, on the one hand, a limited or even negative role of GH and IGF1 in cancer, longevity, and cardiovascular disease (34, 35, 36), and, on the other hand, the limited evidence for benefit of rhGH substitution in the elderly GHD population and long-term positive effects on QoL (37), long-term rhGH use in GHD adults should be critically re-evaluated. Third, we cannot exclude coexisting hypothalamic damage, especially in case of a history of large tumors with suprasellar extension (38). Obesity is a well-recognized complication in patients treated for tumors in the hypothalamic–pituitary region, which is attributed to compression of surrounding tissues (39). This hypothalamic damage could be an independent factor influencing the metabolic profile in GHD patients. Finally, most patients had multiple pituitary hormone deficiencies, making distinction between effects of rhGH replacement or effects of suboptimal or excessive replacement therapy of other hormones difficult.

Several validated definitions can be applied for the definition of the MS, precluding direct comparisons between studies (40). We used the NCEP-ATP III criteria (23, 24) to be comparable to our previous studies on MS (5, 19). In the NCEP-ATP III criteria, the use of antihypertensive, anti-diabetic, and lipid-lowering medication is incorporated. In the original description of the NCEP-ATP III criteria, statins are not specifically mentioned. However, the lipid-lowering effects of statins are well established in the general population, and thereby significantly influencing the lipid criteria of the MS (41).

We found sex-specific differences in MS proportion and the metabolic response to rhGH replacement. In untreated GHD females, MS proportion was very high compared with the general population. This might be in line with a recent report of Van Bunderen et al. (42), describing an increased risk of cardiovascular death in GHD females, despite rhGH substitution. The increased incidence in cardiovascular deaths in females might partly be attributed to the more atypical presentation of cardiovascular diseases (43) or inadequately substituted hypogonadism causing preterm menopause or hypocortisolism. The most predominant increase in the MS proportion during rhGH replacement in males further supports that the cardiovascular risk pattern in GHD patients is sex-specific.

When compared with other population-based control cohorts, such as the MORGEN cohort (1993–1997) or the Tromsø Study (1994–1995) (44), the MS proportion found in the Leiderdorp cohort was nearly doubled (30.3% in Leiderdorp cohort vs 15.7% in the MORGEN cohort and 19.2% (males) and 17.8% (females) in the Tromsø Study)
(5). As the same criteria for MS were applied, we expect that
this increase in MS proportion most likely reflects the
increase in BMI and an increased use of antihypertensive
medication in the general population over 15 years and
emphasizes the importance for a contemporary compari-
sion group from the general population.

The strength of the present study is the availability of
large recent population-based control data and the
inclusion of analysis on the crude metabolic laboratory
data in addition to the age-, sex-, and BMI-adjusted
analysis using the NCEP-ATP III criteria of MS. Our
relatively large middle-aged GHD cohort reflects the
best-case scenario, in which hormonal suppletion of all
pituitary axes is optimized and adequately monitored.
A potential limitation could be the fact that we evaluated
the MS proportion in the untreated GHD situation only in
patients in whom rhGH replacement was actually
initiated. This could introduce a selection bias, because
GHD patients without rhGH replacement are likely to
differ from patients who actually received rhGH replace-
ment. Second, it has to be noted that the patients in our
GHD cohort are very heterogeneous with respect to the
cause of GHD, failure of other pituitary hormone axes,
and history of cranial irradiation and/or surgery, which
may have influenced the results. Third, we only reported the
metabolic parameters included in the MS according to the
NCEP-ATP III criteria, not for example LDL-C or body fat
percentages, which are also GH-dependent parameters.
Another feature that needs to be addressed is the presence
of interactions between glucocorticoids and rhGH during
substitution. In the past, hydrocortisone suppletion in
hypopituitary patients frequently resulted in supraphy-
substitution. This could introduce a selection bias, because
GHD patients without rhGH replacement are likely to
differ from patients who actually received rhGH replace-
ment. Second, it has to be noted that the patients in our
GHD cohort are very heterogeneous with respect to the
cause of GHD, failure of other pituitary hormone axes,
and history of cranial irradiation and/or surgery, which
may have influenced the results. Third, we only reported the
metabolic parameters included in the MS according to the
NCEP-ATP III criteria, not for example LDL-C or body fat
percentages, which are also GH-dependent parameters.
Another feature that needs to be addressed is the presence
of interactions between glucocorticoids and rhGH during
substitution. In the past, hydrocortisone suppletion in
hypopituitary patients frequently resulted in supraphy-

in our cohort hydrocortisone doses of 20 mg/day or less during the entire follow-up period
and cortisol levels were highly monitored, we expect that
in our cohort hydrocortisone oversupplementation is not likely
to have negatively influenced the results. In this respect,
it has also been noted that minor thyroid dysfunction
and insufficient thyroid replacement have a significant
independent negative impact on cardiovascular risk
factors in hypopituitary adults (45), further emphasizing
the importance of adequate hormonal suppletion of all
deficient pituitary axes. In addition, it would be ideally
preferred to include a longitudinal follow-up control
group for comparison; however, such a control group
was not available in The Netherlands. Finally, it has to
be noted that a priori GHD patients are more likely to
receive anti-diabetic and/or lipid-lowering medication
than controls in case of lipid and/or glucose abnormalities,
as these patients are regularly followed up at the
Department of Endocrinology, which is not the case for
controls without a history of pituitary disease.

In conclusion, despite 5 years of rhGH replacement,
GHD patients still have a different metabolic profile and a
higher MS proportion than the general population. These
differences were independent of BMI and resemble the
metabolic profile of untreated GHD patients. This empha-
sizes the need for further study to establish whether rhGH
replacement is actually beneficial in the long-term,
adequately incorporating the cost-effectiveness, QoL,
and the potential negative effects of GH/IGF1 on cancer,
longevity, and cardiovascular risk.

Declaration of interest
The authors declare that there is no conflict of interest that could be
perceived as prejudicing the impartiality of the research reported.

Funding
The NEO Study is supported by the participating Departments, the Division,
and the Board of Directors of the Leiden University Medical Centre, and by
the Leiden University, Research Profile Area ‘Vascular and Regenerative
Medicine’.

Acknowledgements
The authors thank Dr N van Duinen, Dr N E Kokshoorn, Dr A A van der
Klaauw, E de Lange, and D M M M Adoptie for their help with the data
collection of GHD patients during the yearly GH control visits at the
outpatient clinic. In addition, they thank the NEO Study Group, the NEO
research team, and participants of the NEO Study.

References
1 Rosen T & Bengtsson BA. Premature mortality due to cardiovascular
0140-6736(90)91812-O)
2 Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS,
Sheppard MC & Stewart PM. Association between premature mortality and
hypopituitarism. West Midlands Prospective Hypopituitary Study
04006-X)
3 Maisen P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B &
Chanson P. Impact of growth hormone (GH) treatment on cardio-
vascular risk factors in GH-deficient adults: a Metaanalysis of Blinded,
Randomized, Placebo-Controlled Trials. Journal of Clinical Endocrinology
and Metabolism 2004 89 2192–2199. (doi:10.1210/jc.2003-030840)
4 Attanasio AF, Mo D, Erfurth EM, Tan M, Ho KY, Kleinberg D,
Zimmermann AG & Chanson P. Prevalence of metabolic syndrome in
adult hypopituitary growth hormone (GH)-deficient patients before
and after GH replacement. Journal of Clinical Endocrinology and
Metabolism 2010 95 74–81. (doi:10.1210/jc.2009-1326)
5 van der Klaauw AA, Biermasz NR, Feskens EJ, Bos MB, Smit JW,
Roelisma F, Corssmit EP, Pijl H, Romijn JA & Pereira AM. The


Received 24 September 2013
Revised version received 1 November 2013
Accepted 11 November 2013